STALEY CAPITAL ADVISERS’s Medicus Pharma MDCX Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio MDCX Stock Details MDCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.61K	Buy	+200	New	+$2.78K	﹤0.01%	200

Other funds holding MDCX

Interchange Capital Partners Pittsburgh, Pennsylvania $598M AUM 31.79% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $606M AUM 21.78% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

May Hill Capital Cohasset, Massachusetts $510M AUM 23.75% 1-Year Est. Return

Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return

Smithfield Trust Pittsburgh, Pennsylvania $2.51B AUM 13.63% 1-Year Est. Return

Summit Global Investments Bountiful, Utah $2.02B AUM 17.87% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

STALEY CAPITAL ADVISERS's MDCX Position: Q3 2026 in Review

STALEY CAPITAL ADVISERS opened a new position in Medicus Pharma (MDCX) in Q3 2026: 200 shares worth $1.61K. The stake represents ﹤0.01% of the portfolio and ranks #200 among its holdings.

11 funds tracked by Wall St. Rank hold MDCX as of Q3 2026.

STALEY CAPITAL ADVISERS held 200 shares of Medicus Pharma worth $1.61K as of Q3 2026.
Medicus Pharma was a new STALEY CAPITAL ADVISERS position in Q3 2026.
Medicus Pharma made up ﹤0.01% of STALEY CAPITAL ADVISERS's portfolio in Q3 2026, its #200 holding.
11 funds tracked by Wall St. Rank held Medicus Pharma as of Q3 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2026, filed 6 Nov 2026.